Klinkhamer Group | conferences & events
Newsletter 6
11th World Congress on Alternatives and Animal Use in the Life Sciences
Free Live WC11 webinars on 
3Rs in COVID-19 research
25 and 26 August 2020 | 3 PM CET
On 25 and 26 August 2020 at 3 PM CET, WC11 will organize two 1.5 hour webinars on 3Rs in COVID-19 research. On both days, several excellent presentations will highlight innovative model systems to study COVID-19, and will also discuss new strategies for the development of vaccines, therapeutics and diagnostics and much more!
Please find below a brief overview of the program. For a more detailed version of the program, please visit our website by clicking the button below. 
Tuesday 25 August 2020
03:00 PM | Welcome and introduction by moderator Brian Maguire

03:05 PM | Presentation by Penny Hawkins
Head of Research Animals Department, RSPCA, United Kingdom
03:25 PM | Presentation by Koert Stittelaar
General Manager, Viroclinics Xplore, Schaijk, The Netherlands

03:45 PM | Presentation by Christian Desaintes
Policy Officer, European Commission, Belgium

04:05 PM | Discussion speakers and questions

04:30 PM | Closure by moderator Brian Maguire
Wednesday 26 August 2020
03:00 PM | Welcome and introduction by moderator Brian Maguire

03:05 PM | Presentation by Thomas Hartung

Director CAAT, Johns Hopkins University, United States of America

03:25 PM | Presentation by Shuibing Chen
Kilts Family Associate Professor, Director of Diabetes Program, Department of Surgery, Weill Cornell Medicine, United States of America

03:45 PM | Presentation by Jan Willem van der Laan
Senior Assessor Pharmacology and Toxicology, Medicines Evaluation Board, Chair Safety Working Party CHMP, EMA, The Netherlands

04:05 PM | Discussion speakers and questions

04:30 PM | Closure by moderator Brian Maguire
FINAL virtual seats available. Register now!
With the webinar series coming closer, the virtual seats are almost all fulfilled. Be quick and secure your seat to make sure you will be able to take part in the webinar series!
Is there a role for the 3Rs in COVID-19 research?
In the past few weeks we have asked several people to answer the question: "Is there a role for the 3Rs in COVID-19 research?". Every week we will send you the answers we received from scientists all over the world.
Marize Campos Valadares
Director of the Laboratory of Education and Research in In Vitro Toxicology, Universidade Federal de Goiás (Brazil)
“The world is facing the biggest challenge of our generation with the spread of COVID-19, demanding speedy actions in discovering new therapeutic tools. Usually, innovation in pharmaceutical science is a very expensive and time-consuming process with no guarantees of success. Strategies in the context of 3Rs for drugs/vaccines discovery and development for COVID-19 treatment can accelerate the process as well as reduce the risk of failures. For instance in safety evaluations, new approach methods can predict mutagenicity/genotoxicity or even skin sensitization potential within days, instead of months using animal models. In terms of animal reductions, in the traditional full safety package, it is possible to combine animal studies, for example, carcinogenicity with chronic oral toxicity studies. Another example is vaccine batch control testing, one of most animal-consuming areas in regulatory testing, where in vitro potency assays can be performed. The drug/vaccine discovery research for COVID-19 treatments definitely can benefit from the advances in 3Rs. Artificial intelligence, in vitro, in chemico, and in silico models/high-throughput screening methods can play a crucial role to facilitate research and success in development of medicines/vaccines for COVID-19."
Marina Goumenou
Research affiliate of Center of Toxicology Science & Research, Medical School, University of Crete, Senior Scientific Officer of General Chemical State Laboratory (Greece)
“The COVID-19 pandemic has severe health effects and serious implications for economic growth and social development. In this context, the scientific community has played an exemplary role in responding to this global emergency, prioritizing research into this disease. As the quest to find suitable vaccines and/or drugs follows an unprecedented swiftness, it is also time to emphasize the importance of the 3Rs implementation in COVID-19 research. A major difficulty in animal studies results from the lack of animal models that reflect the common pathology in the majority of COVID-19 patients, including infection dynamics and transmission, as well as similar immune response to vaccine candidates. Here, the application of new (animal-free) approach methodologies, such as human in vitro assays of different complexity ranging from high-throughput assays, 2D or 3D cellular models and human tissue slices to organ-on-a-chip approaches, can be proven to be extremely useful, allowing research based on specific features of human biology. Such approaches comply with the Directive 2010/63/EU, in which the principle of the 3Rs needs to be considered when selecting testing approaches to be used for regulatory testing of human and veterinary medicinal products, and may provide vital and swift data for a safe progression to clinical testing."
11th World Congress on Alternatives and Animal Use in the Life Sciences
E. info@wc11maastricht.org
T. +31 (0)43 362 70 08
Follow us on Social Media:
This email was sent to
You received this email because you are registered to the WC11 mailing list.
© 2020 Klinkhamer Group | conferences & events